US paediatricians say Covid cases in children on the rise
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[WASHINGTON] Coronavirus cases in children in the United States have risen 32 per cent from about two weeks ago, a spike that comes as the country rushes to inoculate children before the winter holiday season, paediatricians said.
More than 140,000 children tested positive for the coronavirus from Nov 11-18, up from 107,000 in the week ending Nov 4, according to a statement on Monday from the American Academy of Pediatrics and the Children's Hospital Association.
These cases accounted for about a quarter of the country's caseload for the week, the statement said. Children younger than 18 make up about 22 per cent of the US population.
"Is there cause for concern? Absolutely," Dr Sean O'Leary, the vice chair of the academy's infectious diseases committee, said in an interview on Monday night. "What's driving the increase in kids is there is an increase in cases overall."
Children have accounted for a greater percentage of overall cases since the vaccines became widely available to adults, said Dr O'Leary, who is also a professor of pediatrics at the University of Colorado School of Medicine and Children's Hospital Colorado.
Although children are less likely to develop severe illness from Covid than adults, they are still at risk and can also spread the virus to adults. Experts have warned that children should be vaccinated to protect against possible long-Covid symptoms, multisystem inflammatory syndrome and hospitalisation.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
At the end of October, about 8,300 American children ages 5-11 have been hospitalised with Covid and at least 172 have died, out of more than 3.2 million hospitalisations and 740,000 deaths overall, according to the Centers for Disease Control and Prevention.
At a news conference Friday, Dr Janet Woodcock, acting commissioner of the Food and Drug Administration, said hospitalisations and deaths among 5- to 11-year-olds were "really startling." Dr O'Leary said it did not help that many schools had softened their safety protocols in the past few months.
"So any protection that might be happening in schools is not there," he said.
Vaccinations of younger children are likely to help keep schools open. Virus outbreaks forced about 2,300 schools to close between early August and October, affecting more than 1.2 million students, according to data presented at a CDC meeting Nov. 2.
O'Leary said he was especially concerned about case increases in children during the holiday season.
With the pace of inoculations stagnating among US adults, states are rushing to encourage vaccinations for children 5-11, who became eligible this month after the CDC authorised the Pfizer-BioNTech vaccine for that age group. In May, the federal government recommended making the Pfizer-BioNTech vaccine available to children ages 12-15. Teenagers 16 and older became eligible in most states a month earlier.
The White House estimated Nov 10 that nearly 1 million young children had gotten vaccinated; 28 million are eligible. They receive one-third of the adult dose, with two injections three weeks apart.
All of the data so far indicates that the vaccines are far safer than a bout of Covid, even for children.
Still, about 3 in 10 parents say they will definitely not get the vaccine for their 5- to 11-year-old child, according to a recent poll by the Kaiser Family Foundation. Only about 3 in 10 parents said they would immunise their child "right away."
NYTimes
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance
‘Largest Singapore commercial S-Reit proxy’: analysts say buy CICT shares after Paragon acquisition
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Why where you park your joint venture matters: Lessons from a US$689 million shareholder dispute